Monday, February 22nd, 2016
|
|
|
|
Workshop: Immunogenicity Prediction
Noel Smith (Lonza) |
Tuesday, February 23rd, 2016
|
|
|
|
Keynote lecture: Determinants of Immunogenicity and Tolerance
Abul Abbas (University of California San Francisco) |
|
|
|
Increase of drug tolerance: An alternative to acid dissociation
Jad Zoghbi (Sanofi) |
|
|
|
Pre-Existing Antibodies: When do they matter? What to do with them?
Lakshmi Amaravadi (Sanofi) |
|
|
|
Immune response against particles in protein therapeutics
Matthew Baker (Abzena) |
|
|
|
Lessons learnt from the European Experience Regarding Biosimilars and Immunogenicity
Paul Chamberlain (NDA) |
|
|
|
Immunogenicity of recombinant biologics: Post-translational and chemical modifications
Roy Jefferis (University of Birmingham) |
Wednesday, February 24th, 2016
|
|
|
|
Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk
Anna Fogdell-Hahn (Karolinska Institutet) |
|
|
|
Immunogenicity of Biopharmaceuticals
Jack A. Ragheb (Eli Lilly Co) |
|
|
|
Immunogenicity Prediction: Where are we?
Noel Smith (Lonza) |
|
|
|
B- and T-cell Epitope prediction
Paolo Marcatili (Technical University of Denmark) |
|
|
|
Draft EMA Immunogenicity Guideline
Pekka Kurki (Finnish Medicines Agency) |
|
|
|
FDA Immunogenicity Updates
Susan Kirshner (CDER/FDA) |
|
|
|
Scientific update
Tim Hickling (Abirisk) |
